SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the initiation of patient screening in the
second and third Phase 3 pivotal trials evaluating the efficacy and safety of
its lead drug candidate, lorcaserin hydrochloride, for weight management in
overweight and obese patients. Known a...
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that Phillip M. Schneider and Randall E. Woods
were appointed to its board of directors. Mr. Schneider and Mr. Woods are
Arena's seventh and eighth independent directors and bring significant
financial and biotechnology industry operat...
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it is scheduled to provide an overview of
the company, including its clinical development and discovery programs, at two
upcoming investor conferences:
19th Annual Piper Jaffray Health Care Conference
...
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007 at
10:20 a.m. Eastern Time (7:20 a.m. Pacific Time) at the Waldorf=Astoria Hotel
in New York City. Jack Lief, Arena...
SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today the pricing of its public offering of
11,000,000 shares of its common stock at a public offering price of $9.91 per
share. All of the shares are being offered by Arena. The underwriters have a
30-day option to purchase up to an addition...
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 6,
2007 at 12:20 p.m. Eastern Time (9:20 a.m. Pacific Time) at the New York
Palace Hotel in New York City. ...
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
BIOCOM Investor Conference on November 2, 2007 at 1:00 p.m. Pacific Time (4:00
p.m. Eastern Time) at the Marriott Del Mar Hotel in San Diego, California.
Jack Lief, Arena's President and ...
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it has filed a preliminary prospectus
supplement to a shelf registration statement with the Securities and Exchange
Commission relating to a proposed public offering of 10,000,000 shares of its
common stock. In connection with thi...
SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the third quarter ended
September 30, 2007.
Total revenues in the third quarter of 2007 were $5.0 million, compared to
$4.4 million in the third quarter of 2006. Total revenues in the first nine
months ...
SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report financial results for the third
quarter 2007 after the NASDAQ Global Market closes on Wednesday, October 17,
2007. That same afternoon, Jack Lief, Arena's President and Chief Executive
Officer, and Robert E. Hoffman, Are...
SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to provide a
corporate overview of its clinical development and discovery programs at two
upcoming investor conferences:
Natixis Bleichroeder Hidden Gems Conference
Presentation...
SAN DIEGO, Sept. 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it has been selected to be one of the
inaugural companies in the new NASDAQ® NeuroInsights® Neurotech Index.
The NASDAQ NeuroInsights Neurotech...
SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced positive preliminary results from its Phase 2
clinical trial of APD125 in patients with chronic insomnia. APD125 is an
orally available drug candidate discovered by Arena that is being evaluated in
insomnia patients who have difficult...
SAN DIEGO, Sept. 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
UBS Global Life Sciences Conference on September 24, 2007 at 2:00 p.m. Eastern
Time (11:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack
Lief, Arena's President and Chief Exec...
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to provide a
corporate overview of its clinical development and discovery programs at four
upcoming investor conferences:
ThinkEquity Partners' 5th Annual Growth Conference
...
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that an independent Echocardiographic Data
Safety Monitoring Board (the Board or EDSMB) found no reason to stop the
ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin
for Overweight and Obesity Management). T...
SAN DIEGO, Sept 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
Bear Stearns 20th Annual Healthcare Conference on September 11, 2007 at
3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel in
New York City. ...
SAN DIEGO, Aug 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
NewsMakers in the Biotech Industry Conference on September 6, 2007 at
10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the Millennium Broadway
Hotel in New York C...
SAN DIEGO, July 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the second quarter ended
June 30, 2007.
Total revenues in the second quarter of 2007 were $4.8 million, compared
to $9.3 million in the second quarter of 2006. Total revenues in the first
...
SAN DIEGO, July 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it initiated dosing in a Phase 1 clinical
trial evaluating APD791, Arena's orally administered, internally discovered
drug candidate intended for the treatment of arterial thrombo-embolic
diseases. This Phase 1 trial is planned to...
